Zydus Lifesciences receives 6 observations from USFDA for Gujarat API unit
Zydus Lifesciences on Saturday stated it obtained six observations from the US Food and Drug Administration (USFDA) following a surveillance inspection of its energetic pharmaceutical ingredient (API) manufacturing facility in Dabhasa, Gujarat.In a regulatory submitting, the corporate said that the inspection was performed between April 21 and April 25, 2025.“We wish to inform that the […]




